<DOC>
	<DOCNO>NCT01351103</DOCNO>
	<brief_summary>This primary purpose study find recommended dose LGK974 single agent combination PDR001 safely give adult patient select solid malignancy effective standard treatment available .</brief_summary>
	<brief_title>A Study LGK974 Patients With Malignancies Dependent Wnt Ligands</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Diagnosis locally advance metastatic cancer progress despite standard therapy effective standard therapy exist histological confirmation one following disease indicate : Single Agent Dose escalation part : document BRAF mutant colorectal cancer pancreatic adenocarcinoma . In addition , tumor histological origin document genetic alteration upstream Wnt signal pathway eligible prior agreement Novartis . Single Agent Dose expansion part : document BRAF mutant colorectal cancer document RNF43 mutation and/or RSPO fusion pancreatic adenocarcinoma document RNF43 mutation . In addition , patient tumor histological origin document genetic alteration upstream Wnt signal pathway ( e.g . RNF43 RSPO fusion ) eligible prior agreement Novartis LGK974 PDR001 : Dose escalation : melanoma patient primary refractory antiPD1 inhibitor . Dose expansion : patient pancreatic cancer , TNBC , melanoma , head neck cancer . Impaired cardiac function Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption oral LGK974 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) Brain metastases adequately treat Malignant disease treat study Laboratory abnormality specify protocol Osteoporosis , severe untreated osteopenia Bone fracture within past year Pathologic bone fracture Active , know suspected autoimmune disease severe hypersensitivity reaction monoclonal antibody Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>LGK974</keyword>
	<keyword>pancreatic adenocarcinoma</keyword>
	<keyword>BRAF mutant colorectal cancer</keyword>
	<keyword>tumor type document genetic alteration upstream Wnt signal pathway</keyword>
	<keyword>RNF43 mutation</keyword>
	<keyword>RSPO fusion</keyword>
	<keyword>melanoma</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>PDR001</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>head neck cancer</keyword>
</DOC>